Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

stryker corp. - SYK

SYK

Close Chg Chg %
367.36 -2.90 -0.79%

Closed Market

364.46

-2.90 (0.79%)

Volume: 1.27M

Last Updated:

Mar 28, 2025, 3:59 PM EDT

Trade Now

Company Overview: stryker corp. - SYK

SYK Key Data

Open

$368.51

 Day Range

363.28 - 368.51

52 Week Range

314.93 - 405.81

 Market Cap

$140.29B

Shares Outstanding

381.69M

 Public Float

357.05M

Beta

0.95

 Rev. Per Employee

N/A

P/E Ratio

47.38

 EPS

$7.86

Yield

88.10%

 Dividend

$0.84

EX-DIVIDEND DATE

Mar 31, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.54M

  

SYK Performance

1 Week
 
 -1.78%
 
1 Month
 
 -5.62%
 
3 Months
 
 -0.71%
 
1 Year
 
 1.85%
 
5 Years
 
 128.93%
 

SYK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 33
Full Ratings ➔

About stryker corp. - SYK

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

SYK At a Glance

Stryker Corp.
1941 Stryker Way
Portage, Michigan 49002
Phone 1-269-385-2600 Revenue 22.60B
Industry Medical Specialties Net Income 2.99B
Sector Health Technology 2024 Sales Growth 10.23%
Fiscal Year-end 12 / 2025 Employees 53,000
View SEC Filings

SYK Valuation

P/E Current 48.038
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 46.387
Price to Sales Ratio 6.145
Price to Book Ratio 6.655
Price to Cash Flow Ratio 32.729
Enterprise Value to EBITDA 24.338
Enterprise Value to Sales 6.571
Total Debt to Enterprise Value 0.095

SYK Efficiency

Revenue/Employee 426,320.755
Income Per Employee 56,471.698
Receivables Turnover 5.667
Total Asset Turnover 0.545

SYK Liquidity

Current Ratio 1.949
Quick Ratio 1.323
Cash Ratio 0.59

SYK Profitability

Gross Margin 61.823
Operating Margin 22.35
Pretax Margin 15.455
Net Margin 13.246
Return on Assets 7.222
Return on Equity 15.26
Return on Total Capital 8.612
Return on Invested Capital 9.494

SYK Capital Structure

Total Debt to Total Equity 68.431
Total Debt to Total Capital 40.628
Total Debt to Total Assets 32.859
Long-Term Debt to Equity 60.904
Long-Term Debt to Total Capital 36.16
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Stryker Corp. - SYK

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
17.11B 18.45B 20.50B 22.59B
Sales Growth
+19.21% +7.84% +11.11% +10.23%
Cost of Goods Sold (COGS) incl D&A
6.40B 7.41B 8.00B 8.63B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
990.00M 998.00M 1.03B 1.05B
Depreciation
371.00M 371.00M 393.00M 427.00M
Amortization of Intangibles
619.00M 627.00M 635.00M 623.00M
COGS Growth
+14.31% +15.78% +8.03% +7.77%
Gross Income
10.71B 11.04B 12.49B 13.97B
Gross Income Growth
+22.35% +3.09% +13.17% +11.81%
Gross Profit Margin
+62.60% +59.84% +60.95% +61.82%
2021 2022 2023 2024 5-year trend
SG&A Expense
7.05B 7.31B 8.21B 8.92B
Research & Development
1.24B 1.23B 1.29B 1.41B
Other SG&A
5.81B 6.08B 6.92B 7.50B
SGA Growth
+21.43% +3.66% +12.41% +8.60%
Other Operating Expense
- - - -
-
Unusual Expense
1.06B 853.00M 334.00M 1.29B
EBIT after Unusual Expense
2.60B 2.88B 3.95B 3.76B
Non Operating Income/Expense
21.00M 139.00M 82.00M 124.00M
Non-Operating Interest Income
68.00M 94.00M 75.00M 139.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
337.00M 337.00M 356.00M 396.00M
Interest Expense Growth
- +6.98% +5.64% +11.24%
Gross Interest Expense
337.00M 337.00M 356.00M 396.00M
Interest Capitalized
- - - -
-
Pretax Income
2.28B 2.68B 3.67B 3.49B
Pretax Income Growth
+16.73% +17.62% +36.90% -4.93%
Pretax Margin
+13.33% +14.54% +17.92% +15.45%
Income Tax
287.00M 325.00M 508.00M 499.00M
Income Tax - Current - Domestic
252.00M (12.00M) 284.00M 580.00M
Income Tax - Current - Foreign
272.00M 279.00M 430.00M 289.00M
Income Tax - Deferred - Domestic
(105.00M) (209.00M) (232.00M) (538.00M)
Income Tax - Deferred - Foreign
(132.00M) 267.00M 26.00M 168.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.99B 2.36B 3.17B 2.99B
Minority Interest Expense
- - - -
-
Net Income
1.99B 2.36B 3.17B 2.99B
Net Income Growth
+24.70% +18.25% +34.22% -5.43%
Net Margin Growth
+11.66% +12.78% +15.44% +13.25%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.99B 2.36B 3.17B 2.99B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.99B 2.36B 3.17B 2.99B
EPS (Basic)
5.2891 6.2348 8.3377 7.8556
EPS (Basic) Growth
+24.21% +17.88% +33.73% -5.78%
Basic Shares Outstanding
377.00M 378.20M 379.60M 381.00M
EPS (Diluted)
5.2158 6.1695 8.2486 7.7619
EPS (Diluted) Growth
+24.05% +18.28% +33.70% -5.90%
Diluted Shares Outstanding
382.30M 382.20M 383.70M 385.60M
EBITDA
4.65B 4.73B 5.31B 6.10B
EBITDA Growth
+23.66% +1.74% +12.19% +14.90%
EBITDA Margin
+27.19% +25.65% +25.90% +27.00%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 430.76
Number of Ratings 33 Current Quarters Estimate 2.717
FY Report Date 03 / 2025 Current Year's Estimate 13.452
Last Quarter’s Earnings 4.01 Median PE on CY Estimate N/A
Year Ago Earnings 12.19 Next Fiscal Year Estimate 14.873
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 25 27 27
Mean Estimate 2.72 3.14 13.45 14.87
High Estimates 2.98 3.29 13.67 15.37
Low Estimate 2.65 3.01 13.25 13.87
Coefficient of Variance 2.24 2.16 0.96 1.95

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 18 17
OVERWEIGHT 6 6 6
HOLD 9 9 9
UNDERWEIGHT 1 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Stryker Corp. - SYK

Date Name Shares Transaction Value
Feb 28, 2025 Ronda E. Stryker Director 3,299,776 Bona fide gift 0.00
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer 35,729 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $96.64 per share 3,452,850.56
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer 32,798 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $391.74 per share 12,848,288.52
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2025 Ronda E. Stryker Director 3,807,334 Bona fide gift 0.00
Feb 20, 2025 Allan C. Golston Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Allan C. Golston Director 14,895 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $383.07 per share 5,705,827.65
Feb 20, 2025 Allan C. Golston Director 17,353 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $385.18 per share 6,684,028.54
Feb 20, 2025 Allan C. Golston Director 18,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $122.51 per share 2,266,435.00
Nov 8, 2024 Ronda E. Stryker Director 3,186,635 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $367.6 per share 1,171,407,026.00
Nov 8, 2024 Ronda E. Stryker Director 3,267,748 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $365.53 per share 1,194,459,926.44
Nov 8, 2024 Ronda E. Stryker Director 3,086,608 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $370.07 per share 1,142,261,022.56
Nov 8, 2024 Ronda E. Stryker Director 3,087,772 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $369.37 per share 1,140,530,343.64
Nov 8, 2024 Ronda E. Stryker Director 3,126,983 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $368.5 per share 1,152,293,235.50
Nov 8, 2024 Ronda E. Stryker Director 3,235,663 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $366.57 per share 1,186,096,985.91
Aug 9, 2024 Ronda E. Stryker Director 3,316,608 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $326.06 per share 1,081,413,204.48
Aug 9, 2024 Ronda E. Stryker Director 3,321,611 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $325.45 per share 1,081,018,299.95
Aug 9, 2024 Ronda E. Stryker Director 3,339,538 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $324.48 per share 1,083,613,290.24
Aug 9, 2024 Robert Fletcher VP, Chief Legal Officer 9,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 4, 2024 Glenn S. Boehnlein VP, Chief Financial Officer 22,852 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $336.5 per share 7,689,698.00

Stryker Corp. in the News